Hodgkin's Disease Clinical Trial
Official title:
Hodgkin's Lymphoma: Prognostic Value of the Kinetic of Decrease of 5 Cytokines Concentration During Treatment
More than 90% of patients with Hodgkin lymphoma (HL) can recover thanks to conventional
polychemotherapy regimens - ABVD or BEACOPP - with or without radiotherapy. Nevertheless,
some patients relapse and others are resistant to any treatment. These patients represent
2-5% of stage I / II and 5-10% of disseminated stages. The usual prognostic index based on
clinical and biological data (supradiaphragmatic HL: EORTC and advanced HL International
Prognostic Score) cannot always detect patients at risk.
New prognostic factors are required to screen out these high risk patients. Among available
biological factors, we will retain the cytokines secreted by tumor cells and cells from the
environment.
Indeed, the prognostic value of plasma cytokines levels and their soluble receptors has
recently been described by at least two teams. Olivier CASASNOVAS set up a prognostic index
based on quantities of IL-1 RA, IL-6, sCD30 and TNFR1 at diagnosis,and the V. Diehl team
published the prognostic value of the decrease of TARC (CC Thymus and Activation-related
chemokine).
In daily practice, the early assessment of response by PET CT-scan is now an undeniable
prognostic factor. Early identification of no-response or relapse is, in fact, based on
clinical and imaging (PET-CT scan).
We propose to evaluate the decrease of cytokines concentration with a prognostic value (TARC,
IL-6, IL1-RA, sCD30, TNFR1) as markers of response during treatment and during early
follow-up. The dosage of these cytokines will be paired with radiological assessments.
A correlation between the decrease of cytokines plasma levels overtime and event-free
survival will be searched afterwards.
To evaluate the decrease of cytokines concentration with a prognostic value as markers of
response, the dosage of TARC, IL-6, IL1-RA, sCD30 and TNFR1 will be performed during
treatment at :diagnosis, cycle 1 day 15, cycle 2 Day 1, cycle 3 Day 1, Day 1 of consolidation
(Cycle 5 day 1 or before radiotherapy) and evaluation of end of treatment.
an early follow-up with a dosage of cytokines will be performed 3 months after the end of
treatment.
An evaluation for Event Free Survival will be done at 3 years from diagnosis.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01665768 -
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
|
Phase 2 | |
| Completed |
NCT01188798 -
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 3 | |
| Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
| Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
| Completed |
NCT00150462 -
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT02856646 -
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
|
||
| Completed |
NCT01458288 -
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
|
Phase 2 | |
| Completed |
NCT00990587 -
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
|
Phase 1 | |
| Terminated |
NCT00594308 -
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
N/A | |
| Completed |
NCT00469729 -
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
|
Phase 2/Phase 3 | |
| Completed |
NCT00552825 -
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
|
N/A | |
| Completed |
NCT00165438 -
Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy
|
N/A | |
| Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
| Recruiting |
NCT02007811 -
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
|
Phase 1/Phase 2 | |
| Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00665314 -
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
|
Phase 2 | |
| Completed |
NCT00569842 -
Investigation of the Cylex® ImmuKnow® Assay
|
N/A | |
| Completed |
NCT00256191 -
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00284804 -
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
|
Phase 2 | |
| Completed |
NCT00396201 -
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
|
Phase 2 |